BPTS BIOPHYTIS SA AMERICAN DEPOSITARY SHARE

Biophytis: RESULTS OF THE ANNUAL GENERAL MEETING ON JUNE 16, 2023 ALL RESOLUTIONS PRESENTED BY THE COMPANY HAVE BEEN ADOPTED

Biophytis / Key word(s): Miscellaneous
Biophytis: RESULTS OF THE ANNUAL GENERAL MEETING ON JUNE 16, 2023 ALL RESOLUTIONS PRESENTED BY THE COMPANY HAVE BEEN ADOPTED

16-Jun-2023 / 23:00 CET/CEST


RESULTS OF THE ANNUAL GENERAL MEETING ON JUNE 16, 2023

ALL RESOLUTIONS PRESENTED BY THE COMPANY
HAVE BEEN ADOPTED

 

Paris, France and Cambridge (Massachusetts, USA), June 16, 2023 – 11pm CET - Biophytis SA (Nasdaq CM : BPTS, Euronext Growth Paris : ALBPS), («Biophytis» or the «company»), a clinical-stage biotechnology company focused on the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, today announces the approval by a very large majority of all resolutions presented by the company and falling within the remit of the Annual General Meeting.

Thanks to the mobilization of shareholders, the AGM could be held with a quorum of more than 26% of the shareholders present or represented.

The 10 resolutions presented by the company were approved at a very large majority and were notably comprising the approval of the company’s statutory and consolidated accounts for the fiscal year 2022, the allocation of profit & loss for the fiscal year ended December 31, 2022, and the renewal of Mr. Jean Mariani as a board member.

The results of the votes of the Annual General Meeting will be available on Biophytis’ website from June 19, 2023, under the section .

 

*   *   *   *

ABOUT BIOPHYTIS

 

Biophytis SA is a clinical-stage biotechnology company specialized in the development of
therapeutics that are aimed at slowing the degenerative processes associated with aging and
improving functional outcomes for patients suffering from age-related diseases, including severe
respiratory failure in patients suffering from COVID-19.  Sarconeos (BIO101), our leading drug
candidate, is a small molecule, administered orally, planned to be developed as a treatment for
sarcopenia in upcoming Phase 3 clinical trials in the United States, Brazil, and Europe (SARA-31 and
SARA-32). It has also been studied in a clinical two-part Phase 2-3 study (COVA) for the treatment
of severe respiratory manifestations of COVID-19 in Europe, Latin America, and the US. A paediatric
formulation of Sarconeos (BIO101) is being developed for the treatment of Duchenne Muscular
Dystrophy (DMD). The Company is based in Paris, France, and Cambridge, Massachusetts. The
Company's ordinary shares are listed on Euronext Growth (Ticker: ALBPS -ISIN: FR0012816825)
and ADSs (American Depositary Shares) are listed on Nasdaq Capital Market (Ticker BPTS – ISIN:
US09076G1040).

 

For more information, visit .

Disclaimer

 

This press release contains forward-looking statements. Forward-looking statements include all
statements that are not historical facts. In some cases, you can identify these forward-looking
statements by the use of words such as "outlook," "believes," "expects," "potential," "continues,"
"may," "will," "should," "could," "seeks," "predicts," "intends," "trends," "plans," "estimates,"
"anticipates" or the negative version of these words or other comparable words. Such forward-
looking statements are based on assumptions that Biophytis considers to be reasonable. However, there can be no assurance that the statements contained in such forward-looking statements will
be verified, which are subject to various risks and uncertainties. The forward-looking statements
contained in this press release are also subject to risks not yet known to Biophytis or not currently
considered material by Biophytis. Accordingly, there are or will be important factors that could
cause actual outcomes or results to differ materially from those indicated in these statements.
Please also refer to the "Risk and uncertainties the Company is to face" section from the
Company's 2022 Financial Report available on BIOPHYTIS website () and as
exposed in the "Risk Factors" section of form 20-F  as  well  as  other  forms  filed  with  the  SEC
(Securities and Exchange Commission, USA). We undertake no obligation to publicly update or
review any forward-looking statement, whether as a result of new information, future
developments or otherwise, except as required by law.

 

 

 

Biophytis Contact for Investor Relations

Nicolas Fellmann, CFO

 

 

 

Media contacts

Antoine Denry:  – 27

Agathe Boggio:    42

Nizar Berrada:    50

 



Dissemination of a Financial Wire News, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


Language: English
Issuer: Biophytis
14 avenue de l´Opéra
75001 Paris
France
Internet:
ISIN: US09076G1040, FR0012816825
EQS News ID: 1659547

 
End of Announcement - EQS News Service

1659547  16-Jun-2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1659547&application_name=news&site_id=research_pool
EN
16/06/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BIOPHYTIS SA AMERICAN DEPOSITARY SHARE

 PRESS RELEASE

Biophytis Publishes First-Half Financial Results and Provides an Updat...

Biophytis / Key word(s): Half Year Results Biophytis Publishes First-Half Financial Results and Provides an Update on its Business Activities 30-Sep-2024 / 23:00 CET/CEST   Biophytis Publishes First-Half Financial Results and Provides an Update on its Business Activities   Paris (France) and Cambridge (Massachusetts, USA), September 30, 2024 – 11:00pm CET – Biophytis SA (Euronext Growth Paris: ALBPS) (“Biophytis” or the “Company”), a clinical-stage biotechnology company focused on developing treatments for age-related diseases, publishes today its financial results for the firs...

 PRESS RELEASE

Biophytis publie ses comptes semestriels et fait le point sur ses acti...

Biophytis / Mot-clé(s) : Résultat semestriel Biophytis publie ses comptes semestriels et fait le point sur ses activités 30-Sep-2024 / 23:00 CET/CEST   Biophytis publie ses comptes semestriels et fait le point sur ses activités   Paris (France) et Cambridge (Massachusetts, États-Unis), 30 septembre 2024 – 23h00 – Biophytis SA (Euronext Growth Paris : ALBPS), («Biophytis» ou la «Société»), une société de biotechnologie au stade clinique spécialisée dans le développement de traitements pour les maladies liées à l'âge, publie aujourd'hui ses résultats financiers pour le premier ...

 PRESS RELEASE

Biophytis déploie sa stratégie de partenariats et signe deux contrats ...

Biophytis / Mot-clé(s) : Autres/Autres Biophytis déploie sa stratégie de partenariats et signe deux contrats avec des agents locaux en Asie 22-Juil-2024 / 08:12 CET/CEST   Biophytis déploie sa stratégie de partenariats et signe deux contrats avec des agents locaux en Asie     Paris, France, Cambridge (Massachusetts, États-Unis), 22 Juillet 2024 – 7h00 – Biophytis SA (Euronext Growth Paris : ALBPS), (« Biophytis» ou la «Société»), une société de biotechnologie au stade clinique spécialisée dans le développement de traitements pour les maladies liées à l'âge, annonce aujourd’hui...

 PRESS RELEASE

Biophytis deploys its partnership strategy and signs two contracts wit...

Biophytis / Key word(s): Miscellaneous/Miscellaneous Biophytis deploys its partnership strategy and signs two contracts with local agents in Asia 22-Jul-2024 / 08:12 CET/CEST Biophytis deploys its partnership strategy and signs two contracts with local agents in Asia   Paris, France, Cambridge (Massachusetts, USA), 22 July 2024 – 7:00 AM – Biophytis SA (Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a clinical-stage biotechnology company specializing in the development of treatments for age-related diseases, today announces the deployment of its partnership strate...

 PRESS RELEASE

Biophytis obtains IND approval from the FDA to start its phase 2 OBA s...

Biophytis / Key word(s): Miscellaneous/Miscellaneous Biophytis obtains IND approval from the FDA to start its phase 2 OBA study in obesity 11-Jul-2024 / 08:13 CET/CEST Biophytis obtains IND approval from the FDA to start its phase 2 OBA study in obesity   Paris (France) and Cambridge (Massachusetts, USA), July 11, 2024 – 07:00am CET – Biophytis SA (Euronext Growth Paris : ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the  development of  therapeutics for age-related diseases,  today announced that it has received Investigational Ne...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch